Clinical Study to Evaluate Unani Compound Topical Formulation Compared With Topical Cream Hydroquinone 4%

A Randomized, Controlled, Parallel Group, Single Blind Clinical Study to Evaluate The Efficacy and Safety of a Unani Compound Topical Formulation in the Treatment of Kalaf (Melasma) - PGIF

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/09/021159

Enrollment

Registered

2019-09-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Participants will be given: safoof of a unani compound formulation Participants will be advised to apply local application : Participants will be given: safoof of a unani compound for

Eligibility

Inclusion criteria

Inclusion criteria: 1.Participants of any sex aged18-50 years 2.Participants having singly or multiple gray brown macules on face, cheeks, nose, forehead, upper lip and chin. 3.Black patches are symmetrical or asymmetrical distribution

Exclusion criteria

Exclusion criteria: •Participants age 50years •Pregnant and Lactating Women •Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction •Known cases of Immuno-compromised states (HIV/ AIDS, Malignancies etc.) •Participants not willing to attend treatment schedule regularly

Design outcomes

Primary

Measure	Time frame
Assessment of Response to Therapy: Clinical assessment will be done at 0, 2, 4, 6, 8 weeks and the response to treatment will be assessed using the MASI Scoring.Timepoint: 0, 2, 4, 6, 8 weeks.	—

Secondary

Measure	Time frame
Lab InvestigationsTimepoint: At Baseline and After Treatment	—

Countries

India

Contacts

Public ContactProf Qamar Uddin

Reader in central research institute of unani medicine

ccrumnawab@gmail.com8100992044

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026